<p>BioMarin Pharmaceutical Inc. has completed the syndication of a new $2 billion senior secured term loan B facility, in addition to an $800 million term loan A facility, as part of its pending acquisition of Amicus Therapeutics, Inc. The financing package also includes a $600 million senior secured revolving credit facility expected to be entered into in connection with the acquisition. Additionally, BioMarin has priced a $850 million offering of 5.500% senior unsecured notes due 2034 at par. The proceeds from these transactions, along with cash on hand, are intended to fund the consideration for the acquisition of Amicus Therapeutics and related expenses. The closing of the notes offering is expected on February 12, 2026, subject to customary closing conditions. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioMarin Pharmaceutical Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: SF74559) on January 29, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)</p>

ARKG

FOLD

Reuters

iShares Global Healthcare

Ark Genomic Revolution ETF

Amicus Therap

iShares US Pharma

First Trust NYSE Arca Biotech Index Fd

iShares Biotechnology ETF

VanEck Biotech ETF

ALPS Medical Breakthrough

SPDR S&P Biotech

Invesco Nasdaq Biotechnology ETF

VG Health

Invesco Biotechnology & Genome ETF

BioMarin Pharma

BioMarin Secures $2 Billion Term Loan to Fund Amicus Therapeutics Acquisition